Since the effects of GBP1 across different cancers remain elusive and the potential role of GBP1 in anti-tumor immune response has been represented in the previous studies, a comprehensive pan-cancer analysis is urgently needed to explore the possibility of GBP1 being a biomarker for immunotherapy. The gene discussed is GBP1; the disease is neoplasm.